Giants of Cancer Care® Announces the 12th Annual Class of Inductees
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
Click to share this newsletter with your colleagues! We hope to see many of you at the 2024 ASCO Annual Meeting in Chicago! FDA Oncology…
Haeseong Park, MD, MPH, discusses findings from a phase 1 study of epacadostat with preoperative chemoradiation in locally advanced rectal cancer.
In 1992, in an effort to bring novel drugs to market more quickly and meet patient needs in a timely manner, the US Food and…
Rohit Jain, MD, MPH, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, comments on the novel developments in the field of antibody-drug conjugates…
Chimeric antigen receptor (CAR) T-cell therapy has shown promise in patients with late-line refractory multiple myeloma, with response rates ranging from 73 to 98%. To…
Jameel Muzaffar, MD, discusses findings from the phase 2 portion of the FLX475-02 study examining tivumecirnon plus pembrolizumab in HNSCC.
This ESMO Webinar Series is available to all healthcare professionals working in Oncology.
This nonrandomized clinical trial examines the toxicity and efficacy of stereotactic ablative radiotherapy in patients with interstitial lung disease and early-stage non–small cell lung cancer.
On this page you can find all the information regarding the registration fees, process and applicable terms to attend the EHA2024 Hybrid Congress. Join us…
Among an ageing cohort of survivors of childhood cancer, the accumulation of non-major adverse cardiovascular events, including subclinical conditions, increased the risk of major adverse…